ArticleStem cell reports2026
Generation and characterization of iPSC models from HIV-1-positive individuals with divergent clinical outcomes.
Article in Stem cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical outcome of human immunodeficiency virus type-1 (HIV-1) infection varies greatly among individuals, ranging from rapid disease progression to natural viral suppression. While viral and environmental factors contribute, host genetics are considered major determinants of disease trajectory. To enable mechanistic studies of host factors underlying disease outcomes, we generated 50 induced pluripotent stem cell (iPSC) lines from 18 participants of the Multicenter AIDS Cohort Study (MACS), spanning a spectrum of clinical trajectories. Reprogrammed MACS lines are confirmed to be HIV-1 negative and Sendai vector-free. We validate their pluripotency and demonstrate robust differentiation into macrophages capable of productive HIV-1 infection. These MACS-iPSC lines offer a genetically diverse resource to model HIV-1 infection in vitro, where clinical progression is known. Crucially, their capacity to differentiate into HIV-1 target cells and other disease-relevant lineages makes them a powerful tool to uncover host determinants of HIV-1 pathogenesis and advance targeted treatment and curative strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.